Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs
Leyla S. Namazova-Baranova,
Andrey L. Bakulev,
Nikolay N. Murachkin,
Lyudmila N. Nam,
Roman A. Ivanov https://doi.org/10.15690/vsp.v20i5.2322
Abstract
The article shows the key role of IL-17 in the psoriasis pathogenesis and the opportunities of its management via monoclonal antibodies product secukinumab. The review of international randomized trials on clinical efficacy and safety of genetically engineered biologic drug secukinumab in children and adolescents with psoriasis is presented. During treatment periods of 12 to 52 weeks, secukinumab has shown high therapeutic efficacy for psoriasis severity and skin lesion areas and has improved quality of life of children and adolescents according to dynamic assessments of PASI, IGA 0/1 mod 2011 indices, CDLQI questionnaire. The safety profile of secukinumab in children is estimated as favorable and comparable to using it in adults.
Keywords
Supporting agencies: Not specified.
About the Authors
Leyla S. Namazova-Baranova
Research Institute of Pediatrics and Children's Health in “Central Clinical Hospital of the Russian Academy of Sciences”; Pirogov Russian National Research Medical University; Belgorod National Research University
Russian Federation
Disclosure of interest:
Russian Federation
Moscow; Belgorod.
Disclosure of interest:
Leyla S. Namazova-Baranova — receiving research grants and fees for scientific counseling and lecturing from Novartis.
Andrey L. Bakulev
Saratov State Medical University n.a. V.I. Razumovsky
Russian Federation
Disclosure of interest:
Russian Federation
Saratov.
Disclosure of interest:
Andrey L. Bakulev — receiving research grants and fees for scientific counseling and lecturing from Novartis.
Nikolay N. Murachkin
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
Nikolay N. Murachkin — receiving research grants and fees for scientific counseling and lecturing from Novartis.
Lyudmila N. Nam
Medical University Reaviz
Russian Federation
Disclosure of interest:
Russian Federation
Saratov.
Disclosure of interest:
No conflict of interests.
Roman A. Ivanov
National Medical Research Center of Children's Health
Russian Federation
Disclosure of interest:
Russian Federation
Moscow.
Disclosure of interest:
No conflict of interests.
References
1. Kubanov AA, Bogdanova EV. Dermatovenereologic health care delivery management in the Russian Federation. Results of 2018. Vestnik Dermatologii i Venerologii. 2019;95(4):8-23. (In Russ.)
2. Dhar S, Banerjee R, Agrawal N, Chatterjee S, Malakar R. Psoriasis in children: An insight. Indian J Dermatol. 2011;56:262-265.
3. Silverberg NB. Update on pediatric psoriasis. Cutis. 2015;95(3):147-152.
4. de Moll EH, Chang MW, Strober B. Psoriasis in adults and children: Kids are not just little people. Clin Dermatol. 2016;34(6):717-723.
5. Guttman-Yassky E, Krueger JG. Atopic dermatitis and psoriasis: two different immune diseases or one spectrum? Curr Opin Immunol. 2017;48:68-73.
6. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323(19):1945-1960.
7. Eisert L, Augustin M, Bach S, Dittmann M, Eiler R, Folster-Holst R, Gerdes S, Hamm H, Hoger P Horneff G, von Kiedrowski R, Philipp S, Pleimes M, Schlager M, Schuster V, Staubach P Weberschock T, Werner RN, Nast A, Sticherling M. S2k guidelines for the treatment of psoriasis in children and adolescents — Short version part 1. J Dtsch Dermatol Ges. 2019;17(8):856-870.
8. Relvas M, Torres T. Pediatric Psoriasis. Am J Clin Dermatol. 2017;18:797-811.
9. Bronckers IM, Paller AS, van Geel MJ, van de Kerkhof PC, Seyger MM. Psoriasis in Children and Adolescents: Diagnosis, Management and Comorbidities. Paediatr Drugs. 2015;17(5):373-384.
10. Rendon A, Schakel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019;20(6):1475. Published 2019 Mar 23. doi: 10.3390/ijms20061475
11. Blauvelt A, Chiricozzi A. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379-390.
12. Bovenschen HJ, Van de Kerkhof PC, Van Erp PE, et al. Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin. Journal of Investigative Dermatology. 2011;131:1853-1860.
13. Nestle F, Kaplan DH, Barcer J. Psoriasis. N Engl J Med. 2009;361:496-509.
14. Korn T, Bettelli E, Oukka M, Kuchroo VK. IL-17 and Th17 Cells. Annu Rev Immunol. 2009;27:485-517.
15. Eisert L, Augustin M, et al. S2k guidelines for the treatment of psoriasis in children and adolescents — Short version part 2. J Dtsch Dermatol Ges. 2019;17(9):959-973.
16. Dogra S, Mahajan R. Biologics in pediatric psoriasis — efficacy and safety. Expert Opin Drug Saf. 2018;17(1):9-16.
17. Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: Systematic review and economic evaluation. Health Technol Assess. 2017;21(64):1-244.
18. Warren RB, Gooderham M, Burge R, Zhu B, Amato D, Liu KH, Shrom D, Guo J, Brnabic A, Blauvelt A. Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. J Am Acad Dermatol. 2020;82(5):1138-1149.
19. Tangtatco JAA, Lara-Corrales I. Update in the management of pediatric psoriasis. Curr Opin Pediatr. 2017;29(4):434-442.
20. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials. N Engl J Med. 2014;371:326-338.
21. Berg SH, Balogh EA, Ghamrawi RI, Feldman SR. A review of secukinumab in psoriasis treatment. Immunotherapy. 2020;13:3.
22. Augustin M, Jullien D, Martin A, Peralta C. RWE of secukinumab in psoriasis treatment. JEADV. 2020;34:1174-1185. doi: 10.1111/jdv.16180
23. Data on file. COSENTYX Access. Novartis Pharmaceuticals Corp; October 2020. Available from: https://www.novartis.com/news/media-releases/novartis-cosentyx-gains-eu-label-update-first-its-kind-maximise-data-axial-manifestations-psoriatic-arthritis (accessed: 20.10.2021).
24. Инструкция медицинскому применению препарата Козэнтикс, 2021. Available from: https://www.novartis.ru/sites/www.novartis.ru/files/product-info/2021-02-18_Cosentyx_sol_NPIv0_full.pdf (accessed: 20.10.2021).
25. Magnolo N, et al. A phase III open-label, randomized multicenter study to evaluate efficacy and safety of secukinumab in pediatric patients with moderate to severe plaque psoriasis: 24-week results. J Am Acad Dermatol. 2021:S0190-9622(21)02509-3. doi: 10.1016/j.jaad.2021.08.066
26. Bodemer C, Kaszuba A, Kingo K, Tsianakas A, Morita A, Rivas E. Papanastasiou P, Keefe D, Patekar M, Charef P, Zhang L, Cafoncelli S, Papavassilis C. Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial. J Eur Acad Dermatol Venereol. 2020 Oct 17.
27. Федеральные клинические рекомендации. Псориаз. Москва, 2020. Available from: https://cr.minzdrav.gov.ru/#!/recomend/866
28. Galluzzo M, D'Adamio S, Silvaggio D, et al. In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis. Expert Opinion on Biological Therapy. 2020;20(2):173-182. doi: 10.1080/14712598.2020.1708897
29. Deodhar A, Mease PJ, McInnes IB, Baraliakos X, Reich K, Blauvelt A, Leonardi C, Porter B, Das Gupta A, Widmer A, Pricop L, Fox T. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: Integrated pooled clinical trial and post-marketing surveillance data. Arthritis Research & Therapy. 2019;21(1):111. doi: 10.1186/s13075-019-1882-2
Review
For citations:
Namazova-Baranova L.S., Bakulev A.L., Murachkin N.N., Nam L.N., Ivanov R.A. Management of Moderate and Severe Forms of Psoriasis in Children: New Opportunities of Genetically Engineered Biologic Drugs. Current Pediatrics. 2021;20(5):446-450. (In Russ.) https://doi.org/10.15690/vsp.v20i5.2322
Views:
713
Email this article 
